As shown in Fig. 1a, the probability with the same value of recurrence-free survival (RFS) was higher in ER- or Her2-positive patients with low tumor CD36 expression than patients having high CD36 expression (p = 0.039 or 0.0017). This evidence concerns the gene ESR1 and neoplasm.